NY-AQARA
22.6.2021 10:02:04 CEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first smart wall switch targeted for the European market, the Aqara Smart Wall Switch H1 EU. The Wall Switch H1 EU series is Aqara’s first smart wall switch supporting both round European wall boxes and 86 mm square wall boxes. It’s available in Single and Double Rocker versions, as well as in With Neutral and No Neutral versions. Along with the Wall Switch H1 EU, Aqara also introduced the latest Wireless Remote Switch H1 (Double Rocker) to the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005459/en/
Both the Wall Switch H1 EU and the Wireless Switch H1 support the Zigbee 3.0 protocol with better stability, compatibility, responsiveness and energy efficiency1 . Both switches share the award-wining design with a metal frame, which makes the switches more rigid and durable. Moreover, the combination of the Wall Switch H1 EU and the Wireless Switch H1 can be used in a 2-way switch setup without excessive wiring, or to upgrade the existing 2-way setup to a smart one, so that users will be able to control the light or other device from two different places similar to using two hard-wired 2-way switches, or even from any part of the room by voice commands or via local automations.
The Wall Switch H1 EU is compatible with major smart home ecosystems and voice assistants, including Apple HomeKit, Amazon Alexa, Google Assistant, IFTTT, and more2 . The availability of With Neutral and No Neutral versions makes it fit almost all homes, while the With Neutral version supports extra features such as power monitoring and overload protection. Other features of the Wall Switch H1 EU include:
- Convert to Wireless Switch Function : The button of the switch can be remapped so that you will get an extra “wireless switch” while the light or other device will be controlled by automations;
- Overheat Protection : Users can be ensured that their homes are safe and secure;
- LED Indicator Behavior Setting : Users can configure the LED indicator via the Aqara Home app, choosing to turn it off completely, turn it on when the switch is on, or vice versa3 .
The Wireless Switch H1 is a HomeKit-compatible remote switch to control Aqara devices and other HomeKit accessories or to switch between smart home scenes. It comes with a double rocker, and recognizes 7 configurable actions including single click, double click, long press, and dual-button press. It also supports the High-Speed Click Mode, which reduces the response time down to 50 milliseconds4 . The Wireless Switch H1 also features a 5-year battery life, the longest so far among all Aqara battery-powered devices.
The Wall Switch H1 EU and the Wireless Switch H1 are expected to be available in various European and Asian countries via authorized Aqara distributors in the following months. Please check with your regional distributor(s) for product availability.
For more details of the Wall Switch H1 EU and the Wireless Switch H1, please visit our website .
1 |
A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required. |
|
2 |
Integration with some third-party ecosystems may be unavailable by the time of the launch. |
|
3 |
Not all of these options are available for the No Neutral version. |
|
4 |
Only single clicks are recognized in the High-Speed Click Mode. |
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. We provide comprehensive smart home products and solutions that are beautifully designed, affordable and easy to use. Our products range from a variety of sensors to switches, curtain controllers, and door locks, and we have opened more than 400 Aqara Home stores globally to provide more personalized smart home solutions.
We continue to expand our global footprint in the United States, EU, Russia, Southeast Asia, Korea and China, and our online devices have covered 192 countries and territories, serving more than 2 million customers. We aspire to bring smart home technology to every household around the world.
For more information, please visit our website and follow our social platforms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005459/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
